



**VIJAYA
DIAGNOSTIC
CENTRE**

November 7, 2024

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
NSE Symbol: VIJAYA

To,
The Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th floor, Dalal Street,
Mumbai - 400 001
BSE Scrip Code: 543350

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on November 7, 2024s

Ref: Regulation 30 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) as amended from time to time

We hereby inform you that the Board of Directors at its meeting held today i.e., on **Thursday, November 7, 2024**, has, *inter-alia*, considered and approved:

1. The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024.

In terms of the above, we enclose herewith the following:

- a. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024;
 - b. Limited review reports on the standalone & consolidated financial results for the quarter and half year ended September 30, 2024.
2. In continuation to our earlier intimation dated August 26, 2024, wherein Mr. Sheshadri Vasam, submitted his notice of resignation from his position of Chief Operating Officer (COO), the Board of Directors of the Company took note of his cessation w.e.f. November 06, 2024 (end of the day), and accordingly he was relieved from the office of the COO with effect from the aforesaid date.
 3. Allotment of 7,192 equity shares having a face value of ₹1/- each, to the employees of the Company who have exercised the options vested under VDCL Employee Stock Option Plan 2018.

Consequent to aforesaid allotment the issued, subscribed, and paid-up equity share capital of the Company has increased from ₹10,26,22,270/- to ₹10,26,29,462/-.



VIJAYA[®]
DIAGNOSTIC
CENTRE

In terms of Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 ("ESOP Regulations 2021"), the details of shares allotted are annexed herewith as **Annexure I**

The Board Meeting commenced at 12:00 Noon (IST) and concluded at 13:30 hrs (IST).

Kindly take the same on record. Thanking You.

Yours Faithfully,

For **Vijaya Diagnostic Centre Limited**

HANSRAJ
SINGH

Digitally signed by
HANSRAJ SINGH
Date: 2024.11.07
13:34:30 +05'30'

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

Encl.: as above



Annexure I

Disclosure pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021

Sl. No.	Particulars	Details
1.	Company name and address of Registered Office	VIJAYA DIAGNOSTIC CENTRE LIMITED 6-3-883/F, FPA Building, Near Topaz building, Punjagutta, Hyderabad, Telangana, 500082.
2.	Name of the recognised Stock Exchanges on which the company's shares are listed	National Stock Exchange of India Limited BSE Limited
3.	Filing date of the statement referred in regulation 10(b) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with the recognised Stock Exchange	28-01-2022
4.	Filing Number, if any	NSE: Application no. 29833 BSE : Application no. 145677
5.	Title of the Scheme pursuant to which shares are issued, if any	Vijaya Diagnostic Centre Limited Employee Stock Option Plan 2018
6.	Kind of security to be listed	Equity shares
7.	Par value of the shares	₹1/- per share
8.	Date of issue of shares	07-11-2024
9.	Number of shares issued	7,192
10.	Share Certificate No	Not applicable
11.	Distinctive number of the share	102622271 to 102629462 (both inclusive)
12.	ISIN Number of the shares if issued in Demat	INE043W01024
13.	Exercise price per share	₹111.12/- for 7,192 shares
14.	Premium per share	₹110.12/- for 7,192 shares
15.	Total issued shares after this issue	10,26,29,462
16.	Total issued share capital after this issue	₹10,26,29,462
17.	Details of any lock-in on the shares	Not applicable
18.	Date of expiry of lock-in	Not applicable
19.	Whether shares are identical in all respects to existing shares? If not, when will they become identical	All the allotted equity shares pursuant to exercise of stock options are identical to the exiting equity shares of the Company.
20.	Details of listing fees, if payable	Not Applicable.

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Company”) for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm’s Registration No.:128510W

**AMIT
KUMAR
BAJAJ**

Digitally signed by
AMIT KUMAR BAJAJ
Date: 2024.11.07
12:39:35 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

07 November 2024

Membership No.: 218685

UDIN:24218685BKGPQD4183

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063



Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter and year-to-date ended 30 September 2024

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2024	30 June 2024	30 September 2023	30 September 2024	30 September 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	16,860.65	14,242.32	13,612.71	31,102.97	25,485.29	52,502.27
	(b) Other income	480.36	382.53	691.56	862.89	1,277.98	2,143.89
	Total income	17,341.01	14,624.85	14,304.27	31,965.86	26,763.27	54,646.16
2	Expenses						
	(a) Cost of materials consumed	2,132.97	1,715.22	1,606.20	3,848.19	3,009.51	6,284.97
	(b) Employee benefits expense	2,538.18	2,479.29	2,134.68	5,017.47	4,167.02	8,646.48
	(c) Finance costs	606.86	604.77	584.01	1,211.63	1,171.10	2,370.82
	(d) Depreciation and amortisation expense	1,536.69	1,518.87	1,365.52	3,055.56	2,609.58	5,540.59
	(e) Other expenses	5,173.45	4,475.61	4,234.78	9,649.06	7,922.83	16,351.13
	Total expenses	11,988.15	10,793.76	9,925.19	22,781.91	18,880.04	39,193.99
3	Profit before tax and exceptional items [1-2]	5,352.86	3,831.09	4,379.08	9,183.95	7,883.23	15,452.17
4	Exceptional items (Refer Note 4)	-	-	-	-	-	205.00
5	Profit before tax [3-4]	5,352.86	3,831.09	4,379.08	9,183.95	7,883.23	15,247.17
6	Tax expense						
	(a) Current tax	1,205.00	869.00	861.93	2,074.00	1,571.93	3,209.93
	(b) Deferred tax	198.06	75.78	232.25	273.84	426.65	577.04
	Total tax expense	1,403.06	944.78	1,094.18	2,347.84	1,998.58	3,786.97
7	Profit for the period/year [5 - 6]	3,949.80	2,886.31	3,284.90	6,836.11	5,884.65	11,460.20
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of defined benefit liability / (asset)	(4.57)	(4.57)	6.47	(9.14)	12.95	(16.62)
	(b) Income-tax relating to above item	1.15	1.15	(1.63)	2.30	(3.26)	4.18
	Other comprehensive income for the period/year (net of tax)	(3.42)	(3.42)	4.84	(6.84)	9.69	(12.44)
9	Total comprehensive income for the period/year [7 + 8]	3,946.38	2,882.89	3,289.74	6,829.27	5,894.34	11,447.76
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)	1,026.22	1,025.97	1,022.67	1,026.22	1,022.67	1,023.46
11	Other equity						64,308.65
12	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 5)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	3.85	2.82	3.21	6.67	5.76	11.21
	- Diluted (in Rs.)	3.84	2.81	3.20	6.65	5.74	11.18

Notes:

- The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
- The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 07 November 2024. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2024. An unmodified report has been issued by them thereon.
- The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".
- During the previous year, the Company incurred an amount of Rs. 205 lakhs for the evaluation of various acquisitions towards financial, legal and tax due diligence and for market study on the diagnostic business in target geographies. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
- During the quarter and year-to-date ended 30 September 2024, the Company has issued 24,820 and 2,76,577 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
- The Board of Directors of the Company in their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The aforesaid Scheme is subject to the approval of Stock Exchanges, SEBI, Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
- The Board of Directors of the Company had proposed final dividend of Rs. 1 per equity share (Face value of Rs.1 each) for the year ended 31 March 2024 at their meeting held on 08 May 2024. The same was approved by the shareholders in the Annual General Meeting of the Company held on 06 September 2024 and was paid on 13 September 2024.
- The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANA
TH REDDY
Digitally signed by
SURA SURENDRANATH
REDDY
Date: 2024.11.07
12:08:09 +05'30'
Dr. S. Surendranath Reddy
Executive Chairman
DIN Number: 00108599

Place: Hyderabad
Date: 07 November 2024

Standalone Statement of Cash flows		(Rs. in Lakhs except as stated)	
	Particulars	For the period ended 30 September 2024	For the period ended 30 September 2023
(A)	Cash flows from operating activities	(Unaudited)	(Unaudited)
	Profit before tax	9,183.95	7,883.23
	<i>Adjustments for:</i>		
	Depreciation and amortisation expense	3,055.56	2,609.58
	Net gain on sale/retirement of property, plant and equipment	(19.36)	(163.42)
	Interest income under the effective interest method	(266.79)	(329.08)
	Rental income from investment property	(20.00)	(18.00)
	Profit on sale of mutual fund investments (net)	(605.75)	(201.30)
	Loss allowance for trade receivables	-	20.00
	Equity-settled share-based payment transactions (ESOP)	85.00	43.78
	Fair value gain on investments measured at FVTPL	57.17	(550.65)
	Finance costs	1,101.14	1,079.69
	Liabilities no longer required written back	-	(5.49)
	Operating profit before working capital adjustments	12,570.92	10,368.34
	<i>Working capital adjustments:</i>		
Decrease/ (Increase) in trade receivables	289.94	(98.30)	
(Increase) in inventories	(115.20)	(162.74)	
(Increase) in other financial assets	19.50	19.72	
(Increase) in other assets and deposits	(264.38)	(39.42)	
Increase in trade payables	456.71	566.88	
Increase / (Decrease) in provisions and other liabilities	180.37	(9.44)	
Increase in other financial liabilities	143.71	168.30	
Cash generated from operating activities	13,281.57	10,813.34	
Income tax paid, net	(1,692.89)	(1,495.82)	
Net cash flow generated from operating activities	11,588.68	9,317.52	
(B)	Cash flows from investing activities		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other intangible assets and intangible assets under development (including capital advances and capital creditors)	(2,957.33)	(5,016.07)
	Proceeds from sale of property, plant and equipment	27.53	182.47
	Investment in liquid mutual funds/bonds, net	(4,295.65)	(4,868.13)
	Deposits redeemed/(made) having original maturity of more than 3 months, net	(2,115.00)	1,268.53
	Loans given to subsidiaries	(300.00)	-
	Rental income from investment property	20.00	18.00
	Interest received	153.02	474.85
Net cash used in investing activities	(9,467.43)	(7,940.35)	
(C)	Cash flows from financing activities		
	Payment of lease liabilities	(1,919.59)	(1,779.38)
	Proceeds from the exercise of employee stock options	388.80	218.13
	Dividend paid	(1,026.23)	-
Net cash used in financing activities	(2,557.02)	(1,561.25)	
Net increase in cash and cash equivalents (A + B + C)		(435.77)	(184.08)
Cash and cash equivalents at the beginning of the period		1,556.38	2,328.97
Cash and cash equivalents at the end of the period		1,120.61	2,144.89
Cash and cash equivalents as per above comprise of the following:			
	As at	As at	
Particulars	30 September 2024	30 September 2023	
Cash on hand	88.21	62.28	
Balances with banks			
- in current accounts	1,031.69	1,160.32	
- unpaid dividend accounts	0.71	922.29	
Total cash and cash equivalents	1,120.61	2,144.89	
<p>for and on behalf of the Board of Directors of Vijaya Diagnostic Centre Limited</p> <p>SURA SURENDRANATH H REDDY</p> <p>Digitally signed by SURA SURENDRANATH REDDY Date: 2024.11.07 12:09:23 +05'30'</p> <p>Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599</p>			
Place: Hyderabad			
Date: 07 November 2024			

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2024 and year to date results for the period from 01 April 2024 to 30 September 2024 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

- a. Vijaya Diagnostic Centre Limited

Subsidiaries

- b. Medinova Diagnostic Services Limited
- c. VDC Diagnostic (Karnataka) LLP
- d. Medinova Millenium MRI Services LLP
- e. P H Diagnostic Centre Private Limited
- f. Namrata Diagnostic Centre Private Limited (Struck off on 06 April 2024)
- g. Doctorslab Medical Services Private Limited (Struck off on 06 April 2024)

Limited Review Report (Continued)

Vijaya Diagnostic Centre Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of 3 Subsidiaries included in the Statement, whose interim financial results reflect total assets (before consolidation adjustments) of Rs. 6,468.89 lakhs as at 30 September 2024 and total revenues (before consolidation adjustments) of Rs. 1,475.68 lakhs and Rs. 2,864.99 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 279.17 lakhs and Rs. 570.92 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 279.17 lakhs and Rs. 570.92 lakhs, for the quarter ended 30 September 2024 and for the period from 01 April 2024 to 30 September 2024 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 325.87 lakhs for the period from 01 April 2024 to 30 September 2024. as considered in the Statement. These interim financial results have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

**AMIT
KUMAR
BAJAJ**

Digitally signed by
AMIT KUMAR BAJAJ
Date: 2024.11.07
12:38:26 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

07 November 2024

Membership No.: 218685

UDIN:24218685BKGPQC3160



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter and year-to-date ended 30 September 2024

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year-to-date ended		Year ended
		30 September 2024	30 June 2024	30 September 2023	30 September 2024	30 September 2023	31 March 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	18,294.82	15,621.68	13,885.89	33,916.50	25,990.85	54,780.53
	(b) Other income	450.99	356.40	675.10	807.39	1,245.77	2,081.80
	Total income	18,745.81	15,978.08	14,560.99	34,723.89	27,236.62	56,862.33
2	Expenses						
	(a) Cost of materials consumed	2,298.81	1,875.77	1,634.84	4,174.58	3,063.60	6,543.84
	(b) Employee benefits expense	2,783.72	2,735.80	2,181.92	5,519.52	4,266.85	9,021.86
	(c) Finance costs	646.84	626.51	585.25	1,273.35	1,173.50	2,398.98
	(d) Depreciation and amortisation expense	1,683.74	1,663.40	1,368.79	3,347.14	2,615.79	5,699.62
	(e) Other expenses	5,614.00	4,886.41	4,332.59	10,500.41	8,112.02	17,124.94
	Total expenses	13,027.11	11,787.89	10,103.39	24,815.00	19,231.76	40,789.24
3	Profit before tax and exceptional items [1 - 2]	5,718.70	4,190.19	4,457.60	9,908.89	8,004.86	16,073.09
4	Exceptional items (Refer Note 4)	-	-	-	-	-	205.00
5	Profit before tax [3 - 4]	5,718.70	4,190.19	4,457.60	9,908.89	8,004.86	15,868.09
6	Tax expense						
	(a) Current tax	1,282.62	960.87	866.58	2,243.49	1,577.08	3,319.95
	(b) Deferred tax, net	223.61	78.80	233.65	302.41	431.95	584.43
	Total tax expense	1,506.23	1,039.67	1,100.23	2,545.90	2,009.03	3,904.38
7	Profit for the period/year [5-6]	4,212.47	3,150.52	3,357.37	7,362.99	5,995.83	11,963.71
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss						
	(a) Remeasurement of the defined benefit obligations	(4.57)	(4.57)	6.47	(9.14)	12.95	(14.99)
	(b) Income-tax relating to above item	1.15	1.15	(1.63)	2.30	(3.26)	3.77
	Other comprehensive income for the period/year (net of tax)	(3.42)	(3.42)	4.84	(6.84)	9.69	(11.22)
9	Total comprehensive income for the period/year [7+8]	4,209.05	3,147.10	3,362.21	7,356.15	6,005.52	11,952.49
	Profit for the period attributable to:						
	Owners of the Company	4,193.64	3,134.52	3,332.20	7,328.16	5,952.57	11,882.53
	Non controlling interests	18.83	16.00	25.17	34.83	43.26	81.18
	Other comprehensive income attributable to:						
	Owners of the Company	(3.42)	(3.42)	4.84	(6.84)	9.69	(11.68)
	Non controlling interests	-	-	-	-	-	0.46
	Total comprehensive income attributable to:						
	Owners of the Company	4,190.22	3,131.10	3,337.04	7,321.32	5,962.26	11,870.85
	Non controlling interests	18.83	16.00	25.17	34.83	43.26	81.64
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 5)	1,026.22	1,025.97	1,022.67	1,026.22	1,022.67	1,023.46
11	Other equity						64,695.88
12	Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 5)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	4.09	3.06	3.26	7.15	5.83	11.62
	- Diluted (in Rs.)	4.08	3.05	3.25	7.13	5.81	11.59

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 07 November 2024. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 30 September 2024. An unmodified report has been issued by them thereon.
3. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
4. During the previous year, the Company incurred an amount of Rs. 205 lakhs for the evaluation of various acquisitions towards financial, legal and tax due diligence and for market study on the diagnostic business in target geographies. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
5. During the quarter and year-to-date ended 30 September 2024, the Company has issued 24,820 and 2,76,577 equity shares of face value of Re. 1/- each respectively on exercise of employee stock options.
6. The Board of Directors of the Company in their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ("the Appointed Date") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The aforesaid Scheme is subject to the approval of Stock Exchanges, SEBI, Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
7. The Board of Directors of the Company had proposed final dividend of Rs. 1 per equity share (Face value of Rs.1 each) for the year ended 31 March 2024 at their meeting held on 08 May 2024. The same was approved by the shareholders in the Annual General Meeting of the Company held on 06 September 2024 and was paid on 13 September 2024.
8. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANA
TH REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2024.11.07
12:10:16 +05'30'

Dr. S. Surendranath Reddy
Executive Chairman
DIN Number: 00108599

Place: Hyderabad

Date: 07 November 2024

Consolidated Balance sheet		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	As at 30 September 2024	As at 31 March 2024
		Unaudited	Audited
	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	41,116.43	37,862.14
	(b) Capital work-in-progress	1,755.18	820.63
	(c) Right-of-use assets	25,240.52	22,354.94
	(d) Goodwill	11,920.49	11,920.49
	(e) Other intangible assets	2,043.75	2,069.70
	(f) Intangible assets under development	88.05	48.67
	(g) Financial assets		
	(i) Investments	4.00	4.00
	(ii) Other financial assets	1,457.59	1,129.95
	(h) Deferred tax assets, (net)	-	291.85
	(i) Other tax assets, (net)	17.50	21.38
	(j) Other non-current assets	1,425.67	618.73
	Total non-current assets	85,069.18	77,142.48
II	Current assets		
	(a) Inventories	663.64	518.27
	(b) Financial assets		
	(i) Investments	15,957.35	10,912.98
	(ii) Trade receivables	1,282.61	1,623.97
	(iii) Cash and cash equivalents	1,467.08	2,224.77
	(iv) Bank balances other than (iii) above	3,712.45	5,082.99
	(v) Other financial assets	3,893.45	312.42
	(c) Other current assets	484.08	457.39
	Total current assets	27,460.66	21,132.79
	TOTAL ASSETS (I + II)	1,12,529.84	98,275.27
	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity share capital	1,026.22	1,023.46
	(b) Other equity	71,462.00	64,695.88
	Equity attributable to owners of the Company	72,488.22	65,719.34
	Non-controlling interest	306.61	271.78
	Total equity	72,794.83	65,991.12
II	Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	26,871.63	23,905.21
	(b) Provisions	1,194.47	1,058.18
	(c) Deferred tax liabilities, (net)	8.26	-
	(d) Other non-current liabilities	31.34	34.17
	Total non-current liabilities	28,105.70	24,997.56
III	Current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	2,288.19	2,013.02
	(ii) Trade payables		
	- Total outstanding dues of micro enterprises and small enterprises; and	51.80	60.45
	- Total outstanding dues of creditors other than micro enterprises and small enterprises	3,754.03	3,234.52
	(iii) Other financial liabilities	4,182.08	1,139.85
	(b) Other current liabilities	488.59	402.43
	(c) Provisions	332.07	315.62
	(d) Current tax liabilities (net)	532.55	120.70
	Total current liabilities	11,629.31	7,286.59
	Total liabilities (II + III)	39,735.01	32,284.15
	TOTAL EQUITY AND LIABILITIES (I + II + III)	1,12,529.84	98,275.27
		<i>for and on behalf of the Board of Directors of</i> Vijaya Diagnostic Centre Limited	
		SURA SURENDRANATH H REDDY	
		Digitally signed by SURA SURENDRANATH REDDY Date: 2024.11.07 12:10:48 +05'30'	
		Dr. S. Surendranath Reddy Executive Chairman DIN Number: 00108599	
Place: Hyderabad			
Date: 07 November 2024			

Consolidated Statement of Cash flows		(Rs. in Lakhs except as stated)	
Sl.No	Particulars	For the period ended	For the period ended
		30 September 2024	30 September 2023
		Unaudited	Unaudited
A.	Cash flow from operating activities		
	Profit before tax	9,908.89	8,004.86
	<i>Adjustments for:</i>		
	Depreciation and amortisation expense	3,347.14	2,615.79
	Net gain on sale/ retirement of property, plant and equipment	(19.36)	(163.42)
	Interest income under the effective interest method	(230.49)	(311.90)
	Profit on sale of mutual fund investments, (net)	(605.75)	(201.30)
	Loss allowance for trade receivables	-	26.01
	Equity-settled share based payment transactions (ESOP)	85.00	43.78
	Fair value gain on investments measured at FVTPL	57.03	(550.65)
	Liabilities no longer required, written back	-	(5.69)
	Finance costs	1,157.52	1,079.69
	Operating profit before working capital changes	13,699.98	10,537.17
	<i>Working capital adjustments:</i>		
	Decrease / (Increase) in trade receivables	341.36	(77.99)
	(Increase) in inventories	(145.37)	(163.92)
	Decrease in other financial assets	0.38	19.72
	(Increase) in other assets and deposits	(283.79)	(41.54)
	Increase in trade payables	510.86	567.67
	Increase / (Decrease) in provisions and other liabilities	195.81	(20.00)
	Increase in other financial liabilities	144.38	166.38
	Cash generated from operations	14,463.61	10,987.49
	Income tax paid, net	(1,950.03)	(1,520.72)
	Net cash inflow from operating activities	12,513.58	9,466.77
B.	Cash flows from investing activities		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other Intangible assets and intangible assets under development (including capital advances and capital creditors)	(4,003.42)	(5,029.95)
	Proceeds from sale of property, plant and equipment	38.46	182.47
	Investment in liquid mutual funds/bonds, net	(4,495.65)	(4,868.12)
	Deposits redeemed/(made) having original maturity of more than 3 months, (net)	(2,148.81)	1,245.48
	Interest received	111.71	469.06
	Net cash used in investing activities	(10,497.71)	(8,001.06)
C.	Cash flows from financing activities		
	Proceeds from the exercise of employee stock options	388.80	218.13
	Dividend paid on equity shares	(1,026.23)	-
	Payment of lease liabilities	(2,136.13)	(1,779.38)
	Net cash used in financing activities	(2,773.56)	(1,561.25)
	Net increase in cash and cash equivalents (A + B + C)	(757.69)	(95.54)
	Cash and cash equivalents at the beginning of the period	2,224.77	2,417.69
	Cash and cash equivalents at end of the period	1,467.08	2,322.15

Cash and cash equivalents as per above comprise of the following:

Particulars	As at	As at
	30 September 2024	30 September 2023
Cash on hand	95.99	63.55
Balances with banks		
- in current accounts	1,203.87	1,336.31
- unpaid dividend accounts	0.71	922.29
- in deposit accounts having maturity less than three months	166.51	-
Total cash and cash equivalents	1,467.08	2,322.15

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANATH
H REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2024.11.07
12:11:21 +05'30'

Dr. S. Surendranath Reddy

Executive Chairman

DIN Number: 00108599

Place: Hyderabad

Date: 07 November 2024